Novartis autoinjector effective for treating psoriasis
pharmafile | September 29, 2021 | News story | Research and Development |
New data show that Novartis Cosentyx (secukinumab) 300-mg single dose autoinjector resulted in high efficacy vs placebo. Cosentyx is a proven medicine, supported by sustained efficacy and safety evidence across several systemic inflammatory conditions, with more than 500,000 patients treated worldwide since launch.
Leading global medicines company, Novartis, announced data from an international Phase IIIb study at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress. These data revealed that treatment with Cosentyx 300 mg in a two mL autoinjector (UnoReady® pen) was effective in treating adults with moderate to severe plaque psoriasis. It also showed convenient administration for patients.
The MATURE study was a randomised, placebo-controlled Phase IIIb study, which assessed the use of a Cosentyx 300 mg autoinjector, versus two 150 mg pre-filled syringes or placebo. Patients who used the autoinjector reported a major improvement in skin clearance, measured by the Psoriasis Area and Severity Index (PASI). Patient satisfaction with the 300mg autoinjector was also high – reaching 100% – with no new safety signals observed over 52 weeks.
As chronic diseases such as psoriasis can be difficult to manage and can significantly reduce a patient’s quality of life, it is vital for newer, simpler and more convenient treatments to be developed and commercialised.
Todd Fox, Global Head of Medical Affairs for Immunology, Hepatology and Dermatology, Novartis, commented: “We’re always looking for ways to improve usability and adherence of all our therapies, so people get the most benefit and treatments are convenient to administer. With the Cosentyx 300-mg autoinjector, people with psoriasis can better manage their symptoms with fewer injections.”
Cosentyx is approved in over 100 countries at doses of up to 300-mg for adults with moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Lina Adams
